首页> 外文会议>International Conference on Electrical, Computer and Communication Engineering >Metabolomic Biomarker Identification for Lung Cancer By Combining Multiple Statistical Approaches
【24h】

Metabolomic Biomarker Identification for Lung Cancer By Combining Multiple Statistical Approaches

机译:通过组合多种统计方法来识别肺癌的代谢物生物标志物

获取原文

摘要

Metabolomic biomarkers are tools that can be used in early disease prediction and drug designing for diseases like lung cancer. Knowing the most differentially expressed metabolites creates a much higher probability of diagnosing lung cancer faster than normal, which can reduce the mortality rate. They are crucial during drug design too. Previously, various works have been done on discovering biomarkers for different diseases. However, it is still nowhere near sufficient since reducing the number of biomarkers and maintaining good classification accuracy are urgent issues in a sector where people's lives are at stake. Thus, to contribute more, in this paper, we have identified the influential metabolites in plasma and serum blood sample for lung cancer and then selected biomarkers from them. We first considered a parametric test (Student's t-test) and two non-parametric tests (Kruskal-Wallis and Mann-WhitneyWilcoxon test) to identify the influential metabolites. We also differentiated the up-regulated and down-regulated metabolites using FC values and heatmap plot. We used SVM classifier to ascertain good accuracy with our set of influential metabolites and ROC Curve Analysis to rank the metabolites and choose biomarkers. Our analysis resulted in 28 influential (p-value <; 0.05) metabolites from plasma sample and 13 influential (p-value <; 0.05) metabolites from serum sample. Finally, 10 metabolites were chosen from each of the samples as respective biomarkers. All the files and codes used in our work are available at https://github.com/Zeronfinity/LungCancerBiomarkers.
机译:代谢组生物标志物是可以在疾病早期预测和药物设计用于像肺癌疾病中使用的工具。知道最差异表达的代谢产生高得多的概率诊断肺癌的速度比正常的,这样可以降低死亡率。他们是药物设计过程中也至关重要。此前,各种工程已在发现的生物标记物对不同的疾病进行。然而,它仍然是因为减少的生物标志物的数量和维护良好的分类精度紧迫问题的部门,人们的生命安全受到威胁远不足够。因此,为了更有助于,在本文中,我们已经确定血浆和血清血样中的影响力的代谢物为肺癌,然后从中选择生物标志物。我们首先考虑的参数测试(学生t检验)和两个非参数检验(秩和检验和Mann-WhitneyWilcoxon测试),以确定有影响力的代谢产物。我们也是有区别的使用FC值和热图情节的上调和下调的代谢物。我们使用SVM分类,以确定良好的精度与我们有影响的代谢物组和ROC曲线分析排名的代谢物和生物标志物的选择。我们的分析导致28有影响(p值<0.05)从血浆样品的代谢物和13有影响(p值<0.05)从血清样品的代谢物。最后,10种代谢物从每个样品作为相应的生物标志物的选择。所有文件,并在工作中使用的代码可在https://github.com/Zeronfinity/LungCancerBiomarkers。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号